VSI/St. Jude
This article was originally published in The Gray Sheet
Executive Summary
Patent litigation settlement agreement announced July 12 calls for Vascular Solutions, Inc. to pay St. Jude 2.5% royalty on sales of its Duett femoral artery closure device in exchange for a non-exclusive license to St. Jude's "Fowler" patents related to sealing devices. The pact also provides for a non-exclusive cross license to VSI's "Gershony" patents if needed by St. Jude, which markets the Angio-Seal femoral artery closure device
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.